Varhaisen vaiheen tutkimus venetoklaxista, lenalidomidista ja rituksimabista/hyaluronidaasista hitaasti kasvavissa lymfoomissa, jotka ovat palanneet hoidon jälkeen tai eivät ole reagoineet hoitoon
Vaiheen I tutkimus Venetoclaxista + Lenalidomidista + Rituksimab Hyaluronidaasista uusiutuneessa tai refraktaarisessa (R/R) indolentissa non-Hodgkinin lymfoomassa (iNHL).
This phase I trial studies the side effects and best dose of venetoclax when given together with lenalidomide and rituximab hyaluronidase in treating patients with follicular lymphoma and marginal zone lymphoma that has come back after treatment (relapsed) or has not responded to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking the action of a protein called Bcl-2, that helps cancer cells survive. Immunotherapy with lenalidomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as rituximab and rituximab hyaluronidase, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this research is to determine if the combination of three drugs, venetoclax, lenalidomide, and rituximab hyaluronidase are safe to administer in patients whose low-grade lymphoma (follicular or marginal zone) has come back after initial therapy or was not responsive to initial therapy.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
- Toistuva marginaalialueen lymfooma
- Tulenkestävä B-soluinen non-Hodgkin-lymfooma
- Toistuva B-solujen non-Hodgkin-lymfooma
- Refractory indolentti aikuisten non-Hodgkin-lymfooma
- Toistuva follikulaarinen lymfooma
- Tulenkestävä follikulaarinen lymfooma
- Refractory marginaalivyöhykkeen lymfooma
- Toistuva laiska aikuisten non-Hodgkin-lymfooma
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
PRIMARY OBJECTIVE:
I. To determine the safety (and the recommended phase 2 dose [RP2D]), of the combination of venetoclax, lenalidomide, and rituximab hyaluronidase in patients with relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL).
SECONDARY OBJECTIVES:
I. To determine the overall response rate (ORR) with rituximab hyaluronidase, venetoclax, and lenalidomide.
II. To determine the 2-year progression-free survival (PFS) with rituximab hyaluronidase, venetoclax, and lenalidomide.
III. To determine the overall survival (OS) following therapy with rituximab hyaluronidase, venetoclax, and lenalidomide.
CORRELATIVE STUDY OBJECTIVES:
I. Describe changes in the level of expression and expression ratio between anti-apoptotic and pro-apoptotic BCL-2 family members before and after therapy with venetoclax/lenalidomide/rituximab hyaluronidase for each patient.
II. Examine the metabolic landscape before and after venetoclax/lenalidomide/rituximab hyaluronidase and their effects on mitochondrial metabolism.
III. Describe the immune effects of venetoclax and its effects on serum cytokines and different immune cell subsets (e.g. B-cells, T-cells, dendritic cells, etc.) in addition to T-cell activation markers and expression of immune checkpoint proteins.
OUTLINE: This is a dose-escalation study of venetoclax.
Patient receive venetoclax orally (PO) once daily (QD) on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21. Patients also receive rituximab intravenously (IV) on days 1, 8, 15, and 22 of cycle 2 and rituximab hyaluronidase (if no significant infusion reaction to rituximab) subcutaneously (SC) on day 1 of cycles 4, 6, 8, 10, and 12. Patients may receive rituximab IV (instead of rituximab hyaluronidase) on days 1, 8, 15, and 22 of cycles 4, 6, 8, 10, and 12 if the patient requires rituximab IV in the opinion of the treating physician. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, and then for up to 5 years.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Todellinen)
Ilmoittautuminen
Vaihe
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Yhdysvallat, 19107
- Sidney Kimmel Cancer Center at Thomas Jefferson University
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
Signed informed consent form
-
Ability and willingness to comply with the requirements of the study protocol
-
Able to swallow oral medications whole
-
Patients must have received at least one prior systemic therapy
-
Histologically confirmed indolent B-cell non-Hodgkin's lymphoma (NHL) of any of the following subtypes recognized by the World Health Organization (WHO) classification: Follicular lymphoma and marginal zone lymphoma. Patients with indolent non-Hodgkin's Lymphoma (iNHL) should have received at least 1 previous prior therapy
-
Patients must have an indication for treatment by Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria in the opinion of the investigator
-
Radiographically measurable disease by computed tomography (CT) scan, defined as at least one node > 1.5 cm in size
-
All study participants must be registered into the mandatory lenalidomide risk evaluation and mitigation strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program
-
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the lenalidomide REMS program
-
Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation. Patients intolerant to aspirin (ASA) may use low molecular weight heparin or equivalent. Inability to take any form of prophylaxis excludes participation
-
Eastern Cooperative Oncology Group performance status of 0, 1, or 2
-
Hemoglobin >= 9 g/dL (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator)
-
Absolute neutrophil count >= 1.0 x 10^9/L (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator)
-
Platelet count >= 75 x 10^9/L (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator)
-
International normalized ratio > 1.5 x upper limit of normal (ULN) for patients not receiving therapeutic anticoagulation
-
Partial thromboplastin time (PTT) or activated PTT (aPTT) =< 1.5 x ULN
-
Creatinine clearance >= 60 mL/min, calculated with the use of the 24-hour creatinine clearance or modified Cockcroft-Gault equation
-
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN
-
Total bilirubin =< 1.5 x ULN (or =< 3 x ULN for patients with documented Gilbert syndrome)
-
Women of childbearing potential must have a negative serum or urine pregnancy test result within 14 days prior to registration
-
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for at least 30 days after the last dose of venetoclax and lenalidomide or 12 months after the last dose of rituximab, whichever is longer * Women must refrain from donating eggs during this same period
* A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus) * Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception
-
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below: * With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least 6 months after the last dose of rituximab and for at least 30 days after the last dose of venetoclax and lenalidomide whichever is longer. Men must refrain from donating sperm during this same period * With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for at least 6 months after the last dose of rituximab to avoid exposing the embryo * The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception
Exclusion Criteria:
Known hypersensitivity to any of the study drugs study drugs
- Known central nervous system (CNS) involvement by lymphoma
- Prior allogeneic stem cell transplant is not permitted if patient is fewer than 4 months from transplant and has either active graft versus host disease or on immunosuppression
- History of severe allergic reactions to humanized monoclonal antibodies
- Prior use of lenalidomide or venetoclax or other BCL2 family inhibitors; prior rituximab is allowed as long as they continue to express CD20 and are not rituximab refractory as defined as: * Did not respond (at least a partial response [PR]) to rituximab or rituximab (R)-chemoregimen therapy * Time to disease progression < 6 months after last rituximab dose
- History of other malignancy that could affect compliance with the protocol or interpretation of results * Patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible * Patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded. Individuals in documented remission without treatment for >= 2 years prior to enrollment may be included at the discretion of the investigator
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient, including renal disease that would preclude chemotherapy administration or pulmonary disease (including obstructive pulmonary disease and history of bronchospasm)
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to registration
- Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin)
- Received the following agents within 7 days prior to registration: * Steroid therapy for anti-neoplastic intent * Strong and moderate CYP3A inhibitors * Strong and moderate CYP3A inducers * Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax
- Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis Presence of positive test results for hepatitis B virus (HBV), hepatitis B surface antigen (HBsAg), or hepatitis C (HCV) antibody * Patients who are positive for HCV antibody must be negative for HCV by polymerase chain reaction (PCR) to be eligible for study participation * Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV deoxyribonucleic acid (DNA) is undetectable. These patients must be willing to undergo monthly DNA testing.
- Known infection with human immunodeficiency virus (HIV) or human T-cell leukemia virus 1 (HTLV-1)
- Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
- Pregnant or lactating, or intending to become pregnant during the study
- Recent major surgery (within 6 weeks prior to the start of cycle 1, day 1) other than for diagnosis
- Malabsorption syndrome or other condition that precludes enteral route of administration
- Known allergy to both xanthine oxidase inhibitors and rasburicase
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Treatment (venetoclax, lenalidomide, rituximab, hyaluronidase)
Patient receive venetoclax PO QD on days 1-28. Beginning cycle 2, patients receive lenalidomide PO QD on days 1-21. Patients also receive rituximab IV on days 1, 8, 15, and 22 of cycle 2 and rituximab hyaluronidase (if no significant infusion reaction to rituximab) SC on day 1 of cycles 4, 6, 8, 10, and 12. Patients may receive rituximab IV (instead of rituximab hyaluronidase) on days 1, 8, 15, and 22 of cycles 4, 6, 8, 10, and 12 if the patient requires rituximab IV in the opinion of the treating physician. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. |
Given PO
Muut nimet:
Given IV
Muut nimet:
Given PO
Muut nimet:
Given SC
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Rate of dose-limiting toxicities
Aikaikkuna: During the first 56 days of therapy
|
Toxicity incidences assessed and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0, will be tabulated by patient cohort. |
During the first 56 days of therapy
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Overall response rate
Aikaikkuna: At the end of 12 month treatment period
|
Defined as the sum of the proportions of patients achieving a complete (CR) or partial response (PR) according to the Lugano Response Criteria. Analyses of efficacy outcomes will be descriptive. A 90% confidence interval will be computed for the best response rate (CR+PR rate) during the 12 month treatment period. |
At the end of 12 month treatment period
|
|
Progression-free survival (PFS)
Aikaikkuna: Time from study registration to documented disease progression or death from any cause, assessed at 2 years
|
PFS distributions will be estimated using the Kaplan-Meier method, and the median PFS along with its corresponding 95% confidence interval will be reported. |
Time from study registration to documented disease progression or death from any cause, assessed at 2 years
|
|
Overall survival (OS)
Aikaikkuna: Time from study registration to death from any cause, assessed at 2 years
|
OS distributions will be estimated using the Kaplan-Meier method, and the median OS along with its corresponding 95% confidence interval will be reported. |
Time from study registration to death from any cause, assessed at 2 years
|
Muut tulostoimenpiteet
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Ilmentymistaso ja ekspressiosuhde anti-apoptoottisten ja pro-apoptoottisten BCL-2-perheen proteiinien välillä mitattuna virtaussytometrilla ja lähettiribonukleiinihapolla (mRNA)
Aikaikkuna: 42 päivää hoidon aloittamisesta hoidon loppuun
|
42 päivää hoidon aloittamisesta hoidon loppuun
|
|
|
Metabolic landscape
Aikaikkuna: 42 days of screening through until end of treatment
|
Adenosine triphosphate (ATP) will be measured by mass spectroscopy and metabolic proteins will described by immunohistochemistry. |
42 days of screening through until end of treatment
|
|
Immune profile
Aikaikkuna: 42 days of starting treatment through until end of treatment
|
Flow cytometry will be used to measure T-cell and B-cell subsetswill be used to quantitate PD-1/PD-L1. |
42 days of starting treatment through until end of treatment
|
|
Immune profile
Aikaikkuna: 42 days of starting treatment through until end of treatment
|
Immunohistochemistry will be used to quantitate PD-1/PD-L1. |
42 days of starting treatment through until end of treatment
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Yhteistyökumppanit
Yhteistyökumppanit
Tutkijat
Tutkijat
- Päätutkija: Ubaldo R Martinez-Outschoorn, MD, Thomas Jefferson University
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Neoplasmat
- Immuunijärjestelmän sairaudet
- Neoplasmat histologisen tyypin mukaan
- Lymfaattiset sairaudet
- Lymfoproliferatiiviset häiriöt
- Immunoproliferatiiviset häiriöt
- Lymfooma, non-Hodgkin
- Lymfooma
- Hemic- ja imusuutteet
- Lymfooma, B-solu
- Lymfooma, follikulaarinen
- Lymfooma, B-solu, marginaalinen vyöhyke
- Aminohapot, peptidit ja proteiinit
- Proteiinit
- Orgaaniset kemikaalit
- Heterosykliset yhdisteet, 1-rengas
- Heterosykliset yhdisteet
- Heterosykliset yhdisteet, 2-rengas
- Heterosykliset yhdisteet, sulatettu rengas
- Karboksyylihapot
- Glykosidihydrolaasit
- Hydrolaasit
- Entsyymit
- Entsyymit ja koentsyymit
- Polysakkaridilyaasit
- Hiilihappio-lyaasit
- Lyaasit
- Piperidiinit
- Vasta -aineet, monoklonaalinen
- Vasta -aineet
- Immunoglobuliinit
- Immunoproteiinit
- Veriproteiinit
- Seerumin globuliinit
- Globuliinit
- Vasta-aineet, monoklonaalinen, hiiren johdettu
- Ftalimidit
- Ftaalihapot
- Hapot, karbosyklinen
- Piperidonit
- Isoindoles
- Lenalidomidi
- Rituksimabi
- Hyaluronoglukosaminidaasi
- Venetoclax
- CT-P10
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- 19P.835
- JT 14408 (Muu tunniste: JeffTrial Number)
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .